retatrutide for pcos WOMEN: on GLP-1 Weight Loss #retatrutide #glp1 #pcos Retatrutide UK 2026: Phase 3
Description
22,23 Obese HFpEF patients have greater LV hypertrophy and pulmonary capillary wedge pressure, increased LV filling pressures and severe right ventricular dysfunction compared with non-obese HFpEF patients
However, GLP-1 RAs may be considered to lower the CV risk in patients with T2D who have a high to very high risk of CVD, (class IIb, level C)
Others gain everything back
Clinical interest has focused on GLP-1 as GIP is no longer active in Type 2 diabetes
If financial constraints mean youll need to stop medication eventually, consider more modest weight loss target that may be more sustainable to maintain
Retatrutide shows superior fat loss in trials up to 24% total body weight vs 21% with Tirzepatide
